A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccination

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210903006

Enrollment

Registered

2021-09-03

Start date

2021-09-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer Safety and Immunological Response Intradermal COVID-19 vaccination

Interventions

Sinovac ID/AstarZenaca ID,AstarZenaca ID/AstarZenaca ID,Pfizer ID/Pfizer ID,AstarZenaca IM/AstarZenaca ID,Pfizer IM/Pfizer ID

Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine

group1,group2,group3,group4,group5

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Males or females at least 18-60 years of age, 2. Have not received any COVID-19 vaccine?, 3. Can understand Thai language through speaking, 4. Able to communicate through electronic tools such as Google form or line, 5.Capable of attending all study visits according to the study schedule., 6. Capable of informed consent and provision of written informed consent before any study procedures

Exclusion criteria

Exclusion criteria: 1. Have history of severe drug or vaccine allergy (anaphylaxis)?, 2. Have detected COVID-19 infection? 3. Have history of COVID-19 high risk contact?, 4. Positive result (s) from either antigen test kit, 5. Have history of Chronic respiratory disease, CVD, CKD, CVS, obesity, cancer and DM?, 6. Have received blood transfusion, plasma, blood product, blood component, immunoglobulins, antiviral or antibodies within the last 90 days?, 7. Have history of cigarettes smoking, alcohol drinking and history of drug abuse?, 8. Being pregnant?, 9. Have unstable disease or could not control the symptom?, 10. Have history of immunodeficiency or been using immunosuppressant or steroid drugs?, 11. Have any unusual symptoms or medical history that considered unable to participate in the study?

Design outcomes

Primary

Measure	Time frame
Immunogenicity response at 2 weeks and 12 weeks after second dose IgG level	—

Secondary

Measure	Time frame
Safety at 7 days after vaccination Adverse event	—

Countries

Thailand

Contacts

Public ContactAssoc. Prof. Somruedee Chatsiricharoenkul

Faculty of Medicine Siriraj Hospital, Mahidol University

somruedee.cha@mahidol.ac.th0816361717

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026